LON:INDV Indivior (INDV) Share Price, News & Analysis GBX 1,238 +19.00 (+1.56%) As of 07/24/2025 Add Compare Share Share Stock Analysis Stock Analysis About Indivior Stock (LON:INDV) Get Indivior alerts:Sign Up Key Stats Today's Range 1,230▼ 1,26450-Day Range 1,238▼ 1,23852-Week Range 548.71▼ 1,264Volume8.46 million shsAverage Volume798,658 shsMarket Capitalization£1.93 billionP/E RatioN/ADividend Yield4.48%Price TargetN/AConsensus RatingN/A Company Overview Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. Read More Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INDV Stock News HeadlinesIndivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround NarrativeOctober 30, 2026 | finance.yahoo.comIndivior Shares Rise After Q3 Adjusted EPS, Revenue Top EstimatesOctober 30, 2026 | finance.yahoo.comPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.November 17 at 1:00 AM | OilPrice (Ad)Indivior Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 29, 2026 | marketscreener.comMIndivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue EstimatesOctober 29, 2026 | finance.yahoo.comIndivior Shareholders Approve Common Stock Issuance for MergerOctober 18, 2026 | theglobeandmail.comIndivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus MergerSeptember 17, 2026 | finance.yahoo.comIndivior制药将于2027年1月终止与利洁时的供应协议September 16, 2026 | cn.investing.comSee More Headlines INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at GBX 1,238 on January 1st, 2026. Since then, INDV shares have increased by 0.0% and is now trading at GBX 1,238. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Reckitt Benckiser Group (RB), Indivior (INVVY), Capita (CPI), Futura Medical (FUM), International Consolidated Airlines Group (IAG), Barclays (BARC) and BP (BP). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:INDV CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-5.57Net Income-£2.36 million Net Margins0.17% Pretax MarginN/A Return on Equity-1.11% Return on Assets2.37% Debt Debt-to-Equity Ratio-107.76 Current Ratio0.89 Quick Ratio1.52 Sales & Book Value Annual Sales£1.40 billion Price / Sales1.38 Cash FlowGBX 461.92 per share Price / Cash Flow2.68 Book ValueGBX (126.42) per share Price / Book-9.79Miscellaneous Outstanding Shares156,209,528Free FloatN/AMarket Cap£1.93 billion OptionableNot Optionable Beta0.19 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (LON:INDV) was last updated on 7/24/2025 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.